Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice daily cytarabine and fludarabine in AML, MDS, and CML
NCT01019317Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2009
- Primary completion
- Sep 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, fludarabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Chronic Myeloid Leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2009; status: completed.
02
Drugs
cytarabinefludarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT01019317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01019317.